The University of Texas at San Antonio is an emerging Tier One research institution with nearly 29,000 students.
Principal Investigator(s)
Ye, JingYong
Funded by
UTSA VPR Office
In the U.S. alone, 2.8 million people sustain a traumatic brain injury (TBI) each year and seek medical care.1,2 However, there are no FDA approved therapies for effective treatment of TBI (or concussion) patients. Current medications are limited to only reducing secondary damage to the brain following TBI, such as using diuretics to reduce the pressure inside the brain by increasing urine output.
